K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · SNY
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | SNY | SANOFI US SERVICES INC | SANOFI US SERVICES INC. | $2.6M | 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient |
| 2026-04-20 | SNY | SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, transparency, vaccines, coverage and access IRA, supply chain integrity, drug pricing in federal programs, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD federal budget issues |
| 2026-04-20 | SNY | SANOFI U.S. | WILLIAMS AND JENSEN, PLLC | $50K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. |
| 2026-04-20 | SNY | SANOFI U.S. SERVICES INC. | W STRATEGIES, LLC | $50K | Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act. Issues around drug pricing. Education on vaccines. |
| 2026-04-19 | SNY | SANOFI U.S. | FORBES-TATE | $50K | Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. |
| 2026-04-19 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tarif |
| 2026-04-18 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2026-04-17 | SNY | SANOFI U.S. SERVICES INC. | MARSHALL & POPP, LLC | $60K | Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patie |
| 2026-04-15 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2026-01-20 | SNY | SANOFI US SERVICES INC | SANOFI US SERVICES INC. | $1.1M | 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Price Negotiations - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 830 (118th) HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5143 (118th) Vaccines Access Improvement Act; HR 5376: Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedne |
| 2026-01-20 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2026-01-20 | SNY | SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, transparency, vaccines, coverage and access IRA, supply chain integrity, drug pricing in federal programs, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD federal budget issues |
| 2026-01-20 | SNY | SANOFI U.S. SERVICES INC. | W STRATEGIES, LLC | $50K | Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act. Issues around drug pricing. |
| 2026-01-20 | SNY | SANOFI U.S. | WILLIAMS AND JENSEN, PLLC | $50K | Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21. |
| 2026-01-20 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $30K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2026-01-18 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole ma |
| 2026-01-17 | SNY | SANOFI U.S. | FORBES-TATE | $50K | Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. |
| 2026-01-16 | SNY | SANOFI U.S. SERVICES INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. |
| 2025-10-20 | SNY | SANOFI US SERVICES INC | SANOFI US SERVICES INC. | $1.6M | Insulin; Taxes- General Issues; Vaccine - General Issues; Pharmacy Benefits Managers (PBMs); and Type 1 Diabetes Screening. 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174; EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; issues related to HR 1 One Big Beautiful Bill; HR 1503: Prescription Information Modernization Act of 2023; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376: Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan |
| 2025-10-20 | SNY | SANOFI U.S. SERVICES INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. |
| 2025-10-20 | SNY | SANOFI U.S. SERVICES INC. | W STRATEGIES, LLC | $50K | Public Law 119-21: One Big Beautiful Bill Act. Implementation of Inflation Reduction Act. |
| 2025-10-20 | SNY | SANOFI U.S. | WILLIAMS AND JENSEN, PLLC | $50K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. H.R. 1, One Big Beautiful Bill Act. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. |
| 2025-10-20 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $30K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2025-10-19 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2025-10-18 | SNY | SANOFI U.S. | FORBES-TATE | $50K | Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. |
| 2025-10-18 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21). Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), insulin price cap, VICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. H.R.1, |
| 2025-10-16 | SNY | SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, transparency, vaccines, coverage and access IRA, supply chain integrity, drug pricing in federal programs, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD federal budget issues |
| 2025-07-21 | SNY | SANOFI US SERVICES INC | SANOFI US SERVICES INC. | $1.1M | 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174; EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; issues related to HR 1 One Big Beautiful Bill; HR 1503: Prescription Information Modernization Act of 2023; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376: Inflation Reduction Act; HR 830: HELP Copays Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap (OOP); Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorizatio |
| 2025-07-21 | SNY | SANOFI U.S. SERVICES INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 1, FY25 budget reconciliation. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation F |
| 2025-07-21 | SNY | SANOFI U.S. | WILLIAMS AND JENSEN, PLLC | $50K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. One Big Beautiful bill. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. |
| 2025-07-21 | SNY | SANOFI U.S. SERVICES INC. | W STRATEGIES, LLC | $50K | H.R.1 - One Big Beautiful Bill Act." Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025. |
| 2025-07-20 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2025-07-20 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tariffs. H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions. Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), insulin price cap, VICP Program, and PBM reform; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescriptio |
| 2025-07-17 | SNY | SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | TARPLIN, DOWNS & YOUNG, LLC | $60K | federal budget issues IRA, transparency, vaccines, coverage and access IRA, supply chain integrity, 340B, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD |
| 2025-07-17 | SNY | SANOFI U.S. | FORBES-TATE | $50K | Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. |
| 2025-07-17 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2025-04-21 | SNY | SANOFI US SERVICES INC | SANOFI US SERVICES INC. | $2.5M | Drug Pricing - General Issues; Taxes- General Issues; Tax Credits; Insurance Design. 340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S. 832; EPIC Act; CDC Type 1 Diabetes Awareness and Education: LHHS approps; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness: LHHS approps; COPD Research Funding: LHHS approps; Delinking; Drug Price Negotiations; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; HR 946- Orphan Drug Negotiation: Orphan Cures Act; HR 1503: Prescription Information Modernization Act of 2023; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376: Inflation Reduction Act; HR 830: HELP Copays Act; HRSA - Type 1 Diabetes Screening: LHHS approps; Influenza Vaccines; Insulin Pricing-General; Insurance Design; Intellectual Property; Out of Pocket Cap (OOP); Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Vouc |
| 2025-04-21 | SNY | SANOFI U.S. SERVICES INC. | MARSHALL & POPP, LLC | $60K | Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7. |
| 2025-04-21 | SNY | SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, transparency, vaccines, coverage and access IRA, supply chain integrity, 340B, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD federal budget issues orphan drug tax credit, vaccine policy |
| 2025-04-21 | SNY | SANOFI U.S. SERVICES INC. | W STRATEGIES, LLC | $50K | Implementation of Inflation Reduction Act. H.R.1492 - EPIC Act of 2025. |
| 2025-04-21 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), insulin price cap, VICP Program, and PBM reform; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rig |
| 2025-04-21 | SNY | SANOFI U.S. | WILLIAMS AND JENSEN, PLLC | $50K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. |
| 2025-04-21 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $30K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2025-04-17 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2025-04-16 | SNY | SANOFI U.S. | FORBES-TATE | $50K | Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines. Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. |
| 2025-03-14 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues related to health care and drug pricing. Issues related to health care and drug pricing. |
| 2025-01-22 | SNY | SANOFI U.S. | WILLIAMS AND JENSEN, PLLC | $50K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158). General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements. |
| 2025-01-21 | SNY | SANOFI US SERVICES INC | SANOFI US SERVICES INC. | $690K | Issues related to Pharmacy Benefit Managers (PBMs); issues related to Vaccines; issues related to Taxes; issues related to over the counter; and issues related to Insulin. Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; general issues related to vaccines; issues related to clinical trial diversity; general issues related to drug pricing; issues related to out of pocket (OOP); general issues to insulin pricing; issues related to Additional Condition for Prescription Use (ACNU); issues related to copay accumulators; issues related to HR3656 "Vaccine Access Improvement Act"; issues related to Vaccine Issues Compensation Program (VICP); issues related to HR 830 "HELP Copays Act"; issues related to Pandemic and All-Hazards Preparedness Act (PAHPA)reauthorization; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues |
| 2025-01-21 | SNY | SANOFI U.S. SERVICES INC. | MARSHALL & POPP, LLC | $60K | Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. Issues related to Type 1 diabetes scre |
| 2025-01-21 | SNY | SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA implementation, transparency, vaccines, coverage and access IRA implementation, supply chain integrity, 340B, orphan drugs, newborn screening, expanded access, transparency, drug shortages, drug pricing, insulin, diabetes screening, COPD federal budget issues orphan drug tax credit, vaccine policy |
| 2025-01-21 | SNY | SANOFI U.S. SERVICES INC. | W STRATEGIES, LLC | $50K | Implementation of H.R.5376 - Inflation Reduction Act of 2022. Issues relating to the Medicaid Drug Rebate Program. Legislation around Vaccine Injury Compensation Modernization. Reauthorization of Pandemic All Hazards Preparedness (PAHPA) Act. H.R.2923 - Living Donor Protection Act of 2023. H.R.5378 - Lower Costs, More Transparency Act. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform. |
| 2025-01-19 | SNY | SANOFI U.S. | FORBES-TATE | $50K | Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers. Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund. Issues related to DOD coverage of type 1 diabetes drugs. Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines; Issues related to DOD coverage of type 1 diabetes drugs. |
| 2025-01-19 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |